Lorlatinib Clinical Trials
8 recruitingDrug
Phase 24Not Applicable1Phase 11Early Phase 11Phase 31
Showing 1–8 of 8 trials
Recruiting
Not Applicable
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
ALK+ Non-Small-Cell Lung Carcinoma
Pfizer90 enrolled31 locationsNCT06487078
Recruiting
Phase 2
Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center30 enrolled1 locationNCT07415005
Recruiting
Phase 1Phase 2
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
Non-small Cell Lung CancerMetastaticRecurrent
Memorial Sloan Kettering Cancer Center56 enrolled6 locationsNCT06007937
Recruiting
Early Phase 1
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
GlioblastomaGlioblastoma MultiformeHigh Grade Glioma+6 more
Nationwide Children's Hospital15 enrolled18 locationsNCT06333899
Recruiting
Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
NeuroblastomaGanglioneuroblastoma, NodularGanglioneuroblastoma
Children's Oncology Group750 enrolled162 locationsNCT03126916
Recruiting
Phase 2
A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib
Non-small Cell Lung Cancer MetastaticALK Gene Mutation
Centro di Riferimento Oncologico - Aviano45 enrolled9 locationsNCT06378892
Recruiting
Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
Real World StudyALK-positive Non-small Cell Lung Cancer
Sichuan Cancer Hospital and Research Institute200 enrolled1 locationNCT06361589
Recruiting
Phase 2
The Drug Rediscovery Protocol (DRUP Trial)
CancerNeoplasmNeoplasia+1 more
The Netherlands Cancer Institute1,550 enrolled36 locationsNCT02925234